Innovative Minds France's Most Impactful Healthcare Leaders

1. MAY ISSUE 01 2024 Innova?ve Minds: France’s Most Impac?ul Healthcare Leads Inves?ng in Tomorrow The Rise of Biomedicine in France Innova?ng for Impact France's Push for Emerging Infec?ous Disease Research Phippe Vwade Presidt and CEO Alzprote Phippe Vwade Architect of Advancements in Drug Discovery

4. Editor’s Note

5. Visionary Medical Minds shaping the future of healthcare. From renowned leaders pushing the boundaries of what’s possible to researchers tirelessly seeking cures for the world’s most challenging diseases, each profile offers a glimpse into the passion, dedication, and ingenuity that fuel their work. Shaping the Future of France’s Healthcare System F surgical techniques to groundbreaking pharmaceutical discoveries, the nation’s rich legacy is interwoven with countless innovations that have transformed patient care globally. rance has long been revered for its contributions to the world of medicine and healthcare. From future-driven We hope that this edition will not only inspire you but also shed light on the invaluable contributions these leaders have made to the healthcare community. Their pursuit of excellence serves as a reminder of the transformative power of innovation and the immense potential it holds for improving human health and well-being. In this special edition, we celebrate the Innovative Minds: France’s Most Impactful Healthcare Leaders. The individuals featured in these pages represent the best and brightest minds dedicated to advancing patient care, pioneering new treatments, and improving overall health outcomes. Their relentless commitment to their craft has yielded innovative discoveries, novel approaches, and a profound impact on countless lives. Join us in celebrating these remarkable individuals and their extraordinary achievements as we explore the innovative minds driving France’s healthcare sector to new heights. Indulge in an insightful read ahead! As you delve into these inspiring stories, you’ll gain insights into the minds that are Natalie May Natalie May - Natalie May

6. Contents Contents Profiles 18 Marie Pirotais Driving Ultimate Progress 28 Nicolas Martelin Pioneering Healthcare Transformation through Innovative Fusion Articles 24 Investing in Tomorrow The Rise of Biomedicine in France 32 Innovating for Impact France’s Push for Emerging Infectious Disease Research

7. 08 Philippe Verwaerde Architect of Advancements in Drug Discovery Cover Story

8. L E A D E R S EUR Health Editor-in-Chief Thanh Truong Managing Editor Pearl Shaw Executive Editor Natalie May Visualiser David King Art & Design Head Samuel Martinez Co-designer Paul Belin Art & Picture Editor Grace Brown Business Development Manager Emily Jones Business Development Executives Anna Smith, Jack Miller Marketing Manager Bill Thompson Sales Executives Mike, Carl, Sandra Technical Consultants David, Robert Assistant Technical Head Joseph Taylor Technical Head Jacob Smile Assistant Digital Marketing Manager Daniel Jones Digital Marketing Manager Alina Sege SME-SMO Executive Gemson Research Analyst Eric Smith Circulation Manager James Carter sales@eurohealthleaders.com MAY, 2024 Contact Us: Insights Success Media and Technology Pvt. Ltd. Survey No.133/134, Brand Square, Office No. 512, Kunjir Chowk, Pimple Saudagar, Pune, Maharashtra 411027. Phone - India: 7410033802, 8956487823 Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com https://twitter.com/eurohealthleaders Insights Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin, OH 43017, United States Phone - +1614-602-4132 Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com Follow us on : www.facebook.com/eurohealthleaders/ We are also available on : Copyright © 2024 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights success. Reprint rights remain solely with Insights Success Media and Technology Pvt. Ltd. Euro Health Leaders is powered by Insights Success Media and Technology Pvt. Ltd.

9. INNOVATIVE MINDS: FRANCE'S MOST IMPACTFUL HEALTHCARE LEADERS Featuring Person Company Brief Caroline Tranvouez is a seasoned professional with extensive experience in the pharmaceutical and cosmetics industry. Caroline Tranvouez Medical Officer Farmea (Groupe Fareva) fareva.com Frederic Desdouits is a versatile professional blending science, finance, and business acumen in the global pharma & biotech sector. Frederic Desdouits CEO Treefrog Therapeutics treefrog.fr Marie Pirotais, a visionary leader with 25 years of R&D experience, drives innovation at Biosency, pioneering non-invasive health monitoring technologies with strategic acumen and market expertise. Marie Pirotais Co-founder and CEO Biosency biosency.com Nicolas Martelin is a forward-thinking leader who is revolutionizing healthcare through the strategic integration of finance and healthcare. Nicolas Martelin President & Co-founder Prostperia prostperia.com Philippe's journey spans pharmacology, entrepreneurship, and biopharmaceutical leadership, driving innovation in neurodegenerative disease treatments, particularly Alzheimer's and tauopathies. Philippe Verwaerde President and CEO Alzprotect alzprotect.com

10. Phippe Vwade Presidt and CEO Alzprote

11. Phippe Vwade Architect of Advancements in Drug Discovery Alzprotect is ready to significantly contribute to advancements in trea?ng neurodegenera?ve diseases in the coming years by focusing on the development and refinement of targeted therapies like AZP2006. Cov Story

12. D edicated healthcare leaders are driven by passion and commitment to contributing meaningfully to the well-being of their communities. Among these leaders is Philippe Verwaerde, an experienced professional who has positively impacted healthcare. With over 35 years of international involvement in academic research, the pharmaceutical industry, and biotech companies, Philippe is known as an innovator and community servant. Philippe’s journey began with achievements in pharmacology within the pharmaceutical and biotech sectors, where he led research teams as a laboratory manager and department director. Subsequently, he ventured into entrepreneurship, co-founding Vivactis in Belgium and iNovacia in Sweden—both players in pharmaceutical discovery and development services. Currently serving as the President and CEO of a biopharmaceutical company in Lille, France, Philippe directs his expertise and passion toward developing innovative treatments for neurodegenerative diseases, including Alzheimer’s disease and tauopathies. Alzprotect Alzprotect , Alzprotect’s mission to create groundbreaking therapeutic solutions addresses a crucial gap in healthcare, as there are currently no available treatments to slow down or halt neurodegenerative diseases, affecting millions worldwide. Philippe’s leadership at Alzprotect shows dedication to a major global health issue. This exclusive feature explores Philippe's inspiring journey, uncovering the qualities that have positioned him as one of France's impactful healthcare leaders. From Microscopes to Metabolic Diseases I love the idea of making a difference in people’s lives. It’s incredible to think that our work could help someone with a serious illness. Philippe, hailing from a working-class family in Northern France, worked hard to become a dedicated scientist. His dream of becoming a researcher began when he received his first microscope at age 11. Philippe recalls, “This gift solidified my determination to pursue a career in biology.” At the age of 14, Philippe achieved his first ‘Philips Scientific Prize for Young Scientists,’ marking the beginning of his scientific journey. This accomplishment was followed by two more recognitions, including the European Young Scientist Award in 1981, leading to his first publication. In 1982, he won the “National Biology

13. Alzprotect—Advancing Neurodegenerative Solutions Competition” and successfully completed his baccalaureate. These achievements led to his doctorate in Biology nine years later, a moment that made his parents proud. Alzprotect, headquartered in Lille, France, stands as a notable biopharmaceutical company, working on neurodegeneration and tauopathies. Focused on developing effective treatments, the company’s mission encompasses the entire journey from drug discovery to proving efficacy in clinical trials for neurodegenerative disorders like Alzheimer’s disease (AD) and Progressive Supranuclear Palsy (PSP). To broaden his horizons and deepen his expertise, Philippe embarked on a journey to the United States, spending two and a half years at Rutgers University (NJ) for further training. By the end of 1993, he returned to Europe to contribute to biotech and pharmaceuticals. Philippe reflects on his international career, recalling, “My journey led me to Italy, Belgium, and Sweden, where I led research teams as a laboratory head and department director before venturing into entrepreneurship.” Philippe underscores the company’s key expertise in tauopathies. He explains, “Our focus lies in understanding diseases where neuronal degeneration is intricately linked to the abnormal accumulation of hyperphosphorylated Tau proteins and neuroinflammation.” This specialized knowledge has led to a groundbreaking discovery in the form of AZP2006, a promising drug candidate Throughout his career, Philippe has overseen various projects in the research and clinical development of innovative drugs, with a keen focus on metabolic diseases, microbiology, and neuroscience.

14. Innova?ve Minds: France's Most Impac?ul Healthcare Leaders demonstrating potent effects in controlling neurodegeneration. The promising outcomes extend to animal studies, where AZP2006 demonstrated a notable improvement in learning and memory. Philippe notes, “This improvement suggests promising outcomes for human patients, especially for Alzheimer’s treatment.” The potential for patients to regain learning abilities and recognize loved ones presents a hopeful prospect, marking a major step in the quest to treat Alzheimer’s disease. AZP2006’s mechanism of action is comprehensive, targeting all known markers of neurodegeneration. Philippe elaborates, “This innovative drug addresses critical factors such as Amyloid beta peptide, Tau protein, Neuroinflammation, and Oxidative stress.” Breakthrough in Neurodegenerative Disease Treatment However, Philippe underlines the importance of future research to validate these findings, noting that confirming these results could be a major advance. in the treatment landscape for Alzheimer’s disease. AZP2006 emerges as a promising drug, carefully designed to target specific processes within brain cells. Its mechanism involves elevating levels of the crucial protein PGRN, integral to the brain’s waste disposal system, known as lysosomes. Philippe emphasizes, “AZP2006 also shows potential in protecting brain cells, promoting their survival and connection, and reducing harmful inflammation.” Strategic Leadership Philippe leads a multidisciplinary team, focusing on the scientific and operational aspects. His leadership is pivotal, with a focus on steering the team through the complexities of neurodegeneration research. Philippe’s responsibilities include a range of important tasks, ranging from resource and budget management to ensuring the seamless alignment of scientific objectives with operational efficiency. The drug’s impact extends to addressing tau pathology, a pivotal feature in various neurodegenerative diseases. AZP2006 achieves this by mitigating harmful protein modifications associated with tau. Philippe further elaborates, “AZP2006 shows a significant positive effect on synaptogenesis, evidenced in neuron cultures and mouse models that fully recovered from severe neurodegeneration.” One of Philippe’s key roles involves thorough resource and budget management, a task essential for supporting project progression while maintaining financial health. Meeting strict regulatory standards stands as a cornerstone of his responsibilities, reflecting a commitment to patient safety and the upholding of research integrity. Recognizing the importance of risk management, Philippe balances project stability with the uncertainties of scientific work. Engaging with stakeholders and collaborating closely with the Chief Medical Officer, Philippe oversees clinical trials, placing high importance on safety and data integrity. His leadership style promotes a culture of innovation in neurodegeneration research, with a strong focus on data analysis and reporting. Promo?ng innova?on in neurodegenera?on research and ensuring effec?ve data analysis and repor?ng are also vital. Overall, my role integrates strategic leadership with scien?fic and opera?onal management. In reflecting on his multifaceted role, Philippe remarks, “Promoting innovation in neurodegeneration research and ensuring effective data analysis and reporting are also vital. Overall, my role integrates strategic leadership with scientific and operational management.” Balancing Passion and Practicality Philippe derives great satisfaction from the multifaceted aspects of his work, focused on improving health and

15. developing medicines. He states, “First and foremost, I find immense joy in the prospect of positively impacting people's lives. It's truly incredible to hope our efforts can help those with serious illnesses.” AZP2006 shows a significant posi?ve effect on synaptogenesis, evidenced in neuron cultures and mouse models that fully recovered from severe neurodegenera?on. The excitement of exploration holds special significance in Philippe’s professional journey. Science, like a complex puzzle, captivates him as he and his team systematically piece together its components. Philippe shares, “Each discovery is an important milestone. – not just for us, but for the fields of science and medicine.” Beyond the confines of the laboratory, Philippe takes pleasure in promoting the growth of the company. The entrepreneurial journey, reminiscent of growing a small idea into a successful enterprise., presents challenges that Philippe approaches with determination. “It's undeniably challenging, but witnessing the company's success is incredibly satisfying,” he observes. results are common.” Effective communication is a necessary skill, allowing clear communication of complex scientific information to the team, partners, and investors. Acknowledging the complexities inherent in his role, such as solving intricate problems and ensuring compliance with safety protocols and regulations, Philippe underscores, “Overcoming challenges makes our successes more rewarding.” The intersection of science and business introduces an additional layer to Philippe’s narrative. Recognizing the mutual relationship, he emphasizes that the company’s financial success not only benefits the team but is also essential for continuing important research and the development of new medicines. Collaboration is deemed vital in this endeavor, requiring Philippe to work closely with a diverse team of scientists, encouraging unified efforts towards common goals. The overall essence of the role involves the combination of scientific expertise, strategic thinking, problem-solving, clear communication, and teamwork. Advancing Innovative Treatments for Neurodegenerative Diseases Philippe adeptly navigates the delicate equilibrium between his passion for science and the pragmatic considerations of managing a business. This equilibrium is paramount in ensuring the continuity of their mission—leveraging the power of science to create a meaningful impact in people's lives. At Alzprotect, the team tackles the development of drug candidates for conditions like Alzheimer’s and tauopathies with a unique focus. Their goal extends beyond merely slowing down or halting the progression of diseases; they aspire to restore neuron connections and enhance brain function. This precise targeting sets Alzprotect apart in the field of neurodegenerative disease research. Navigating the Challenges Leading drug discovery for neurodegenerative diseases requires specific skills. Philippe emphasizes the need for deep understanding of both chemistry and biology, highlighting the importance of staying updated with the latest research developments. Philippe, emphasizing the distinctive approach, notes, “Our approach is grounded in rigorous scientific research and a deep understanding of the molecular mechanisms underlying neurodegeneration such as lysosome dysfunction.” This scientific foundation highlights the commitment to a comprehensive understanding of the intricate processes involved in neurodegenerative conditions. He also highlights the significance of problem-solving in this demanding role, stating, “Problem-solving is key, as challenges like unexpected reactions or ambiguous test

16. In Philippe’s strategic approach, effective communication takes center stage. He aims to communicate complex concepts clearly and engagingly. This entails highlighting breakthroughs and providing updates on clinical trial progress to instill trust and generate interest among investors. Beyond the confines of the boardroom, Philippe actively forges strong relationships through networking with industry leaders, scientists, and investors, recognizing the symbiotic relationship between scientific and financial progress. Acknowledging the inherent risks and expenses associated with drug discovery, especially in challenging areas such as Alzheimer’s, Philippe emphasizes the importance of careful planning. He notes, “Given the risky and expensive nature of drug discovery, especially in areas like Alzheimer’s, I always prepare solid plans for funding usage, risk management, and future steps to reassure investors of our potential.” Furthermore, Philippe maintains a constant focus on long-term goals, understanding that success in biotech and neurodegenerative diseases is a journey that unfolds over years. Charting the Future In the landscape of healthcare’s future, particularly within drug discovery and neurodegenerative disease research, a major shift towards personalized medicine is on the horizon. Philippe underscores this trajectory, stating, “Tailoring treatments like AZP2006 to individual genetic profiles will enhance efficacy and minimize side effects.” Anticipated advancements in biomarkers are poised to significantly improve early detection and intervention in neurodegenerative diseases, potentially altering the course of these conditions. The success achieved in the Phase 2a trials for Progressive Supranuclear Palsy (PSP) stands as evidence to Alzprotect’s dedication to effective and innovative treatments. In a landscape where such advancements are urgently needed, Alzprotect’s progress in clinical trials signal a promising contribution to the evolving field of neurodegenerative disease therapeutics. Balancing Mission and Progress As the leader of a biotech company committed to addressing neurodegenerative diseases, Philippe emphasizes the importance of effectively navigating fundraising and business development. Describing his approach, Philippe highlights, “My approach highlighting our mission to fight diseases. like Alzheimer’s, which affects millions and lacks sufficient treatments. I make sure potential investors and partners grasp the significant impact of our research on healthcare and patients.” The integration of artificial intelligence (AI) and machine learning is set to play a

17. pivotal role, significantly accelerating drug discovery and development processes. Philippe envisions an evolution in treatment approaches, potentially leaning towards combination therapies that address diseases from multiple angles to enhance outcomes. A Visionary Approach to Drug Discovery This era of healthcare promises groundbreaking advancements, marking a shift towards more personalized and effective solutions in neurodegeneration. Philippe affirms, “Alzprotect is ready to significantly contribute to advancements in treating neurodegenerative diseases in the coming years by focusing on the development and refinement of targeted therapies like AZP2006.” The company’s strategic focus revolves around leveraging the promising results from Phase 2a trials for Progressive Supranuclear Palsy (PSP) to further explore and understand the efficacy of their treatments across a spectrum of neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Philippe employs a mul?faceted approach to maintain a holis?c view and cul?vate a vision for future products. His strategies revolve around con?nuous research and development, ensuring Alzprotect stays at the forefront of scien?fic advancements and integrates these insights into its R&D processes. This includes staying well-informed about new discoveries in neurodegenera?ve diseases and emerging technologies in biotech. Insights for Future Leaders in Drug Discovery As an experienced leader in drug discovery and biopharmaceuticals, Philippe shares valuable advice for aspiring professionals looking to make their mark in the field. His guidance centers around developing scientific curiosity, business intelligence, and resilience. Philippe emphasizes, “Stay up to date with the latest scientific advancements and technological innovations, as these are crucial for breakthroughs in drug discovery.” Collabora?on plays a pivotal role as Philippe ac?vely seeks partnerships with leading scien?sts, clinicians, and experts in the field. This collabora?ve effort enables Alzprotect to gain diverse perspec?ves and deepen its understanding of complex challenges. Market trends and pa?ent needs are also cri?cal considera?ons in Philippe’s approach. By keeping a close eye on these factors, he ensures that Alzprotect’s product development aligns with real-world demands, making the company responsive to the evolving healthcare landscape. Networking and collaboration Networking and collaboration are key to success, urging professionals to build robust relationships with peers, mentors, and industry leaders. Philippe advocates for embracing interdisciplinary learning, encouraging a holistic understanding of regulatory landscapes and market dynamics. Most importantly, Philippe concludes, “Be prepared for setbacks and challenges; perseverance and adaptability are vital in this rapidly evolving field where success often comes after numerous trials and learning from failures.” By encouraging the team to think crea?vely and explore novel approaches, Philippe ensures that the company remains adaptable and well-posi?oned in the rapidly evolving field of drug discovery.

19. “ It's not enough to just keep doing what works; to stay ahead we need to keep innovating. - Ron Mobed

20. Marie Pirotais Co-founder and CEO Biosency

21. Innova?ve Minds: France's Most Impac?ul Healthcare Leaders Marie Pirotais Driving Ultimate Progress W Path to Healthcare Innovation ith an intense earnestness for multidisciplinary collaboration where science, technology and business intersect, Marie Pirotais has been driving advancements in various sectors. She holds 25 years of experience in Research and Development (R&D) and innovation departments, where she has honed her expertise in strategy, marketing and project management. One of the most transformative experiences that profoundly shaped Marie’s leadership journey at Biosency was the recognition of the sheer potency in diverse perspectives. Co-founding Biosency alongside Yann Le Guillou, whose distinct background and thought processes diverged from her own, served as a stark revelation of the inherent strength found in diversity. This insight significantly influenced her approach to leadership within their team. In 2015, Marie co-foundedCataris, a consulting company focused on leveraging her diverse skill set to provide strategic insights and solutions to clients. Building on this foundation, she co-founded Biosency in 2017, a pioneering company dedicated to developing a predictive medicine solution based on specialized non-invasive physiological monitoring and digital health solutions. Understanding that diverse perspectives foster innovation and resilience, she actively sought to preserve and encourage this diversity within their organization. It wasn’t solely about individual skills but rather the collaborative intelligence that emerged when an array of unique viewpoints converged. This personal revelation proved instrumental in cultivating an inclusive and innovative culture at Biosency, propelling their collective efforts for personalized, predictive, and participative medicine to unprecedented heights. Marie’s extensive background in R&D, coupled with her strategic acumen and marketing savvy, positions her as a visionary leader in the field of digital health. Her ability to bridge the gap between scientific advancements and market needs has been instrumental in guiding Biosency towards success in developing cutting-edge health monitoring technologies. Marie positioned Biosency as a leader in healthcare innovation and endeavored to meet their ambitious goals through several key strategies: As the Co-founder and CEO of Biosency, Marie continues to drive innovation and spearhead initiatives that push the boundaries of what’s possible in digital health. Her dedication to integrating the latest technologies with a deep understanding of user needs underscores Biosency’s commitment to revolutionizing healthcare through non-invasive monitoring solutions. • Substantial investment in talented R&D, medical, regulatory, and staff, as well as in clinical studies, to bring tangible medical proof to the market on their state-of-the-art predictive medicine solution. This highlighted their commitment to regulatory excellence, achieving CE MDR Class IIa certification as well as ANS certification (French Digital Health Agency) on cybersecurity and interoperability. Let us explore Marie’s transformative journey at Biosency, where innovation meets impact in the world of digital health. May 2024 www.eurohealthleaders.com 19

22. • Prioritization of user experience through intuitive design and implementation of robust data security measures. people worldwide suffer from the disease. COPD is characterized by inflammation and slow, generally progressive obstruction of the bronchial tubes. • Collaboration with state-of-the-art research laboratories, manufacturers, healthcare professionals, and patients’ associations to build long-term partnerships. In 80% of cases, it is linked to smoking, while the remaining 20% are caused by occupational diseases involving dust or pollution. Biosency’s cutting-edge technology harnesses the power of data analytics and real- time monitoring to detect respiratory issues early. Their AI- based predictive solutions improve patient care by enabling healthcare professionals to act upstream and anticipate deterioration in patient health to prevent hospitalization and patient re-admission. • Maintenance of the highest quality standards to meet the challenges of the healthcare sector. They firmly believed that healthcare innovation, if not integrated into a care pathway, would not be able to deliver all its potential added value to the healthcare system. By continuously tracking vital signs and scoring patient health status deterioration, Biosency empowers both patients and healthcare providers with actionable insights, fostering a proactive approach to respiratory care. AI-driven Solutions Founded six and a half years ago, Biosency is a French start-up that provides predictive medicine solutions for patients suffering from chronic respiratory insufficiency. From the beginning, the company has focused on chronic obstructive pulmonary disease or COPD, an under-diagnosed pathology and the third leading cause of death globally. According to the WHO, over 400 million The company is dedicated to staying at the forefront of predictive medicine. Biosency aims to enhance the quality of life for patients and contribute to a more sustainable healthcare ecosystem. May 2024 www.eurohealthleaders.com 20

23. Rising to the Challenge During the height of the first COVID-19 pandemic lockdown in March 2020, Marie recounts the challenging situation Biosency faced when their subcontractor, responsible for manufacturing their cutting-edge Bora band vital sign wristbands, suddenly halted production. BIOSENCY AIMS TO ENHANCE THE QUALITY OF LIFE FOR PATIENTS AND CONTRIBUTE TO A MORE SUSTAINABLE HEALTHCARE ECOSYSTEM. This unexpected disruption left them with a severely limited supply, unable to meet the overwhelming demand from hospitals and pulmonologists for their recently CE DM Class IIa certified remote monitoring solution. This certification was crucial in facilitating the safe return home of patients requiring oxygen therapy. Determined to overcome this obstacle, Marie and her team tapped into their extensive local economic network. Through their efforts, they successfully obtained prefectural authorization to reopen the factory during the lockdown period. This bold and proactive move allowed Biosency to swiftly resume production of their Bora band wristbands, meeting the critical needs of hospitals and pulmonologists who relied on their solution for ensuring the secure at-home recovery of patients on oxygen therapy. Commitment to Innovation and Patient-Centricity Marie emphasizes that at Biosency, the team prioritizes continuous innovation, agility, and patient-centricity, ensuring that their solutions drive tangible improvements in healthcare outcomes. Through strategic collaboration and partnerships, they amplify their impact within the industry, guided by data-driven decision-making, regulatory excellence, and determined ethical standards. With a global vision guiding their international expansion and a steadfast dedication to nurturing talent, they empower a dynamic poised for success. Advancing Respiratory Care Biosency adopts a strategic approach to collaborations and partnerships, aiming to amplify its impact and extend its reach within the healthcare industry. Marie and her team prioritize the establishment of alliances with key stakeholders, including industry leaders, research institutions, and healthcare organizations. Customer feedback holds utmost importance, serving as the driving force behind their adaptability to the ever-changing landscape of healthcare. Rooted in core values of ethics, commitment, professionalism, and trust, these principles foster a culture of unparalleled excellence, resilience, and unwavering responsiveness. At Biosency, it’s their dedicated team that embodies and champions these fundamental values, propelling them towards continued success. By actively engaging patient associations as partners, Biosency ensures that its solutions are not only technologically advanced but also deeply attuned to the needs and experiences of those affected by respiratory conditions. This inclusive approach underscores the company’s commitment to developing patient-centric solutions that address real-world challenges and enhance the overall quality of care. These collaborations serve as catalysts for innovation, enabling Biosency to leverage collective expertise, share knowledge, and remain at the forefront of advancements in medical technology. Listening intently, demonstrating empathy, and valuing the expertise of each individual are the cornerstones of their commitment to shaping the future of respiratory care. May 2024 www.eurohealthleaders.com 21

24. Revolutionizing Healthcare with Predictive Medicine challenges and fostering innovation are paramount for success. First and foremost, she suggests embracing challenges as opportunities for growth and learning. The healthcare landscape is dynamic, and adversity often serves as a catalyst for innovation. With an aging population, a surge in chronic illnesses, the aging of healthcare professionals, and the prevalence of medical deserts, Marie emphasizes the urgent need for transformation in our healthcare system. Biosency aims to play a pivotal role in this transformation by providing the technological foundation to advance predictive medicine and telemonitoring. The integration of telemonitoring not only empowers patients with confidence but also ensures seamless continuity of care at home on a global scale. Therefore, it’s crucial to cultivate an environment that encourages open communication and seamless collaboration within your team and with external partners. Marie emphasizes that it’s the fusion of diverse perspectives that fuels and fortifies strength. She recommends prioritizing patient-centric approaches, developing unyielding resilience, and leading with a blend of empathy and humility. Also, establishing a solid legal framework is paramount to ensure patient safety, device efficacy, and interoperability. Biosency is fully committed to aligning with this framework, paving the way for reimbursement from the French health insurance system. Additionally, the company is diligently preparing for FDA clearance, with approval anticipated by 2025. By embracing these principles, healthcare leaders can not only navigate challenges effectively but also drive a culture of continuous innovation in healthcare. The Roadmap to Success in Healthcare Leadership Marie advises aspiring healthcare leaders that navigating May 2024 www.eurohealthleaders.com 22

26. The Rise of Biomedicine in France May 2024 www.eurohealthleaders.com 24

27. Inves?ng in Tomorrow T principles and biological understanding of the body – supplanted long-held traditional healing practices. This rise of biomedicine as the dominant medical framework was facilitated by the legal system, which increasingly codified it as the only legitimate means of treating patients. he 19th and 20th centuries marked a profound shift in the French medical landscape, as biomedicine – an approach grounded in modern scientific heavily in biomedical innovation to shape the medical breakthroughs of tomorrow. At the heart of France's biomedical boom is a strong commitment from both the public and private sectors to translate groundbreaking research into real-world applications. The French government has made biomedical R&D a strategic priority, allocating significant funding and resources to support scientists, universities, and companies operating in this space. This long-term vision recognizes that the discoveries of today will pave the way for transformative treatments and improved patient outcomes in the years to come. Rise of a New Medical Paradigm In a world where the frontiers of science and medicine are rapidly evolving, France has emerged as a rising force in the pioneering field of biomedicine. This multidisciplinary domain, which integrates principles from biology, engineering, and medicine, holds immense potential to revolutionize healthcare through cutting-edge therapies and technologies. With a rich history of scientific excellence and a forward-thinking approach, France is investing Cell and Gene Therapy Boom One area where France is making notable strides is in the development of advanced cell and gene therapies. These innovative approaches, which harness the power of a May 2024 www.eurohealthleaders.com 25

28. patient's own cells or genetic material, have the potential to address a wide range of diseases in entirely new ways. Several French pharmaceutical giants and emerging biotech companies are at the forefront of this revolution, investing heavily in state-of-the-art production facilities and cutting- edge research programs. the cutting-edge of biomedical science – magnets for the brightest minds from around the globe. These hubs of innovation foster cross-disciplinary collaboration and knowledge-sharing, accelerating the translation of discoveries into marketable products and startups. Facilitating Lab-to-Market Regenerative Medicine Frontiers Recognizing the immense economic potential, both public and private organizations in France are working tirelessly to facilitate this critical path from lab to market. Government initiatives aim to streamline regulatory processes, while technology transfer companies assist in transforming academic projects into commercially viable enterprises. This holistic approach ensures that promising biomedical innovations can rapidly advance from concept to reality. Beyond cell and gene therapies, France is also a hub for pioneering work in regenerative medicine – an exciting field focused on regrowing or restoring damaged tissues and organs. From revolutionary biomaterials that can induce bone regeneration to stem cell therapies that could one day restore function to injured organs, French researchers and companies are pushing the boundaries of what's possible. Another area of focus for France's biomedical ecosystem is leveraging genomic data and precision medicine to tackle rare diseases. Despite impacting millions worldwide, these conditions have historically seen limited investment in research and drug development due to small patient populations. Through ambitious national initiatives, France aims to establish itself as the first country to provide universal access to genomic screening, analysis, and personalized treatments tailored to each individual's unique genetic profile. At the same time, France's ascent as a biomedical leader is attracting significant investment from international pharmaceutical, biotech, and venture capital firms. These companies are drawn by the nation's robust intellectual property protections, business-friendly policies, and access to a large pool of highly skilled talent. As global interest and capital flows into the French biomedical sector, a virtuous cycle of innovation and growth takes hold. Conclusion The potential impact of these biomedical advances is profound – offering hope to patients suffering from devastating illnesses, reducing healthcare costs through more effective treatments, and driving economic growth through a thriving life sciences industry. Indeed, estimates suggest that France's burgeoning biomedical sector could create tens of thousands of high-quality jobs and generate billions in revenue in the years ahead. From the historic halls of the Pasteur Institute to the advanced labs of modern biotech startups, France has a rich scientific heritage that is now catalyzing the next generation of biomedical breakthroughs. By investing today in research, entrepreneurship, and the discoveries that will Define the future of medicine, the nation is positioning itself at the vanguard of a transformative field with the power to enhance human health and longevity on an unprecedented scale. A Rich Research Ecosystem - Natalie May Fueling this biomedical revolution is France's rich research ecosystem and a steadily flowing talent pipeline. The nation boasts world-class universities, institutes, and hospitals at May 2024 www.eurohealthleaders.com 26

30. Nicolas Martelin Pioneering Healthcare Transforma?on through Innova?ve Fusion T affordability. This fusion, though uncommon, ignites transformative progress. Within this arena of opportunity, Nicolas Martelin, President & Co-founder of Prostperia, mirrors the strategic brilliance of visionary leaders. he merging of finance and healthcare emerges as a pathway to new possibilities, paving the way for innovative solutions that enhance accessibility and Martelin collaborated with experts like biologist Brian DeWitt and mathematician Benjamin Chen to develop a superior solution. Their collaborative effort resulted in the creation of the PROSTia test, which was officially introduced with the establishment of Prostperia in 2021. Martelin acknowledged the crucial role played by urologist Pascal Eschwege, whose expertise ensured that the test not only met rigorous scientific standards but also provided tangible benefits for patients and healthcare professionals. Assuming leadership at Prostperia, Martelin is dedicated to revolutionizing healthcare through pioneering solutions. With a background in finance, he seamlessly integrates diverse expertise to drive advancements. As a healthcare leader, Martelin leverages visionary insight to enhance accessibility and affordability, demonstrating steadfast commitment to improving global healthcare outcomes. Mission and Vision Passionately speaking about Prostperia's core mission Martelin highlights their steadfast dedication to patients and the medical community. "From day one, it was clear to Brian, Benjamin, and I that we were doing this for the So, let’s dive in to discover Nicolas Martelin's journey and Prostperia's innovative approach to healthcare transformation! A Journey from Finance to Healthcare Nicolas Martelin's journey from finance to healthcare innovation began with a striking realization: while considerable resources were allocated to financial market research, cancer research was comparatively underfunded. This prompted Martelin to question whether the advanced technology and expertise employed in finance could be leveraged to enhance cancer screening. Martelin's profound reflec?ons highlight the deep connec?on between educa?on and leadership, showcasing how his pedagogical background serves as a founda?on for fostering innova?on and growth within Prostperia. Martelin identified significant flaws in existing screening tests, such as the PSA test for prostate cancer, which he noted, "is wrong half of the time when positive." This led to unnecessary stress and financial burdens for patients and healthcare systems alike. Determined to address this issue, May 2024 www.eurohealthleaders.com 28

31. patients and the medical community," he affirmed. Martelin outlined the company's commitment to delivering patient-centric cancer screening tools, leveraging multiple patient-dependent data points to enhance screening effectiveness. He also emphasized Prostperia's ambitious vision: a shift towards prevention. "Our big vision is to go after a too-often overlooked aspect: prevention," Martelin declared. He explained their goal of transforming screening tests into preventive measures, aiming not only to save trillions of dollars annually but also to extend millions of lives. Martelin underscored the shared belief with Benjamin and Brian that early detection and disease prevention are paramount. "Detecting disease is good, detecting it early is better, and avoiding it is best," he emphasized. Integrating Cutting-Edge Science into Prostperia's Development Nicolas Martelin sheds light on how Prostperia seamlessly integrates cutting- edge scientific principles into their products and services. He highlights their comprehensive approach, leveraging expertise across mathematics, biology, economics, and cognitive science to drive innovation in screening tests. Martelin emphasizes their dynamic exploration of new scientific concepts, always with a clear focus on practical application and impact. Furthermore, he elaborates on their rigorous evaluation process, wherein the potential of new technologies is carefully assessed based on their ability to advance patient care. This meticulous approach ensures that only innovations aligning with the objective of enhancing patient care are considered for integration. Consequently, Prostperia maintains its position at the forefront of healthcare advancement. Nicolas Martelin President & Co-founder Prostperia May 2024 www.eurohealthleaders.com 29

32. Innova?ve Minds: France's Most Impac?ul Healthcare Leaders Fostering Team Growth Through Educational Experience cultivating a sense of hope within the team. "If you share a vision and can convey this idea of hope within your team, you can really propel your team forward," he notes. Reflecting on his dual roles as a lecturer and tutor, he shares profound insights into how his educational background influences his leadership approach at Prostperia. "When you’re in a classroom or when you’re doing tutoring, you have to find ways to get people interested in what you’re saying," he begins. Martelin underscores the importance of captivating an audience's attention, even when the subject matter may seem dry, such as calculus. He elaborates, "You have to give them a reason to learn." Martelin's profound reflections highlight the deep connection between education and leadership, showcasing how his pedagogical background serves as a foundation for fostering innovation and growth within Prostperia. Navigating Challenges as CEO As President of Prostperia, Nicolas Martelin recalls a significant challenge he faced and how he navigated through it. He highlights the experience of developing the second iteration of PROSTia, a screening tool designed to detect prostate cancers. Martelin recalls the initial excitement of creating a tool to identify as many cancers as possible, only to receive unexpected feedback from healthcare professionals. They expressed the need for a screening tool that could differentiate between potential cancers and highlight those with higher risks. Drawing from his experience, Martelin emphasizes the fundamental role of inspiration and hope in education. "On paper, I believe that the recipe for being a good lecturer is simple," he explains. "You have to inspire your students so that they want to listen to you, and you have to instill hope." He passionately advocates for the transformative power of hope, describing it as an "excellent catalyst for progress, resilience, and eventually success." Martelin relates Napoleon Bonaparte's assertion that "a good leader is a dealer in hope" to his own journey, suggesting that his experiences as an educator have shaped his leadership style. "I guess being a lecturer and a tutor taught me to be a leader," he reflects. Martelin highlights the importance of sharing a compelling vision and Acknowledging the initial disappointment, Martelin emphasizes the pivotal moment when he reframed the challenge as an opportunity for growth. Rather than seeing it as a setback, he recognized it as a step towards refining their approach and creating the best screening test possible. Drawing inspiration from Mick Jagger's words, "you can’t always get what you want but if you try, sometimes you get what you need," Martelin highlights the importance of perseverance and adaptability in the face of adversity. From this experience, Martelin learns the value of resilience and the importance of embracing feedback as a catalyst for improvement. He recognizes that setbacks are not failures but rather opportunities for growth and refinement. This mindset shift empowers him and his team to continue their pursuit of innovation, undeterred by challenges along the way. Balancing Local Healthcare Needs with International Aspirations Martelin stresses the global challenge of cancer and the pressing need for better screening methods worldwide. He recognizes the diverse healthcare systems across different countries, making it challenging to design adaptable products. Despite these obstacles, Martelin reaffirms Prostperia's mission to provide accessible screening tests globally, especially in underserved areas. He highlights the concerning disparity in screening access and its impact on cancer rates in certain regions. www.eurohealthleaders.com 30

33. Advice for Aspiring Healthcare Entrepreneurs Currently, PROSTia is only available in France, but Martelin emphasizes their commitment to global expansion. Participation in the La Base accelerator program at HEC Montreal aids in distribution, reflecting Prostperia's dedication to overcoming barriers for global accessibility. On asking about advice for aspiring healthcare entrepreneurs, Nicolas Martelin offers pragmatic guidance. He acknowledges the sector's challenges, such as stringent regulations and lengthy timelines. Martelin advises tackling these hurdles incrementally and highlights the importance of perseverance and resilience. Defining Truly Impactful Leadership Nicolas Martelin believes that truly impactful leaders possess qualities such as hope, resilience, and the ability to zoom out and see the bigger picture amidst challenges. He emphasizes the importance of instilling hope, even in the face of adversity, and the necessity of tapping into an "extra gear" of mental toughness to keep motivation high within the team. He emphasizes the necessity of possessing a profound passion for effecting change in healthcare and encourages individuals to reflect on their commitment to their ideas. Martelin suggests that a willingness to make significant sacrifices indicates being on the right track. To summarize, Martelin's advice focuses on perseverance, passion, and self-reflection as essential for navigating the complexities of the healthcare sector. Martelin draws inspiration from his love for the mountains, which he views as an ideal setting for building mental resilience. He sees his role as embodying these qualities in his leadership style, consistently sharing hope and maintaining a broader perspective to navigate obstacles effectively. He believes that impactful leadership is characterized by hope, resilience, and the ability to rise above challenges. As he states, "The keyword is 'Hope'." May 2024 www.eurohealthleaders.com 31

34. Innova?ng for Impact France’s Push for Emerging Infectious Disease Research I n the aftermath of the COVID-19 pandemic, a harsh reality has come into sharp focus – the world was ill-prepared to respond to a crisis of such unprecedented scale and virulence. As nations around the globe scrambled to contain the spread of the deadly virus, healthcare systems were pushed to their breaking points, economies faced disruption, and society grinded to a halt. The human toll of COVID-19 was staggering, with millions losing their lives and exposing our vulnerability to emerging infectious diseases in an interconnected world. No nation escaped its wrath. From this calamity, a new urgency emerged to fortify global defenses against future pandemics, with France leading with an ambitious plan to spearhead the fight against emerging pathogens. A Multifaceted Approach At the heart of France’s Emerging Infectious Disease Research Plan is a multifaceted strategy that tackles the problem from multiple angles. One key pillar is boosting fundamental virology and immunology research to deepen the understanding of how viral pathogens emerge, spread, and interact with the human immune system. State-of-the-art facilities and cutting-edge scientific equipment will be established to accelerate these research endeavors, creating an environment ripe for groundbreaking discoveries. Funding will also be channeled towards attracting and nurturing top scientific talent from around the world, ensuring that France remains at the vanguard of these critical fields. May 2024 www.eurohealthleaders.com 32

35. May 2024 www.eurohealthleaders.com 33

36. Furthermore, the plan prioritizes the development of innovative diagnostics, therapies, and vaccines against viral threats through innovations in fields like genomics, bioinformatics, and synthetic biology. By harnessing the power of these cutting-edge technologies, researchers aim to expedite the translation of scientific breakthroughs into tangible clinical applications that can save lives during future outbreaks. international effort to enhance pandemic preparedness worldwide. Through collaborative research initiatives, knowledge sharing, and the dissemination of scientific breakthroughs, the impacts of France’s strategic investments in this domain are poised to ripple across borders, benefiting humanity as a whole. Collaborative public-private partnerships between research institutions and pharmaceutical companies will be fostered, recognizing that synergistic efforts are crucial to accelerate the development of effective countermeasures against emerging pathogens. The Road Ahead While the path ahead is arduous, France’s commitment to "Innovating for Impact" in the field of emerging infectious disease research is an alarm of hope in a world still reeling from the devastation of COVID-19. By cultivating a culture of scientific excellence, embracing futuristic technologies, and promoting international collaboration, France is poised to play a major role in mitigating the risks posed by the next global health crisis. Enhancing Surveillance and Prediction Another cornerstone of France’s strategy is the bolstering of real-time disease surveillance and predictive modeling capabilities. By harnessing the power of big data analytics, machine learning, and advanced computational techniques, researchers aim to develop robust early warning systems that can rapidly detect and forecast potential hotspots for outbreaks before they spiral out of control. As the world continues to struggle with the harsh lessons of the COVID-19 pandemic, France’s bold vision serves as a powerful reminder that investing in scientific prowess is not just a matter of intellectual pursuit, but a matter of safeguarding the very fabric of human civilization against existential threats that transcend borders and boundaries. This proactive approach to pandemic preparedness will be fortified by investments in cutting-edge technologies like high-throughput sequencing, which can rapidly identify and characterize novel viral strains as they emerge. By staying ahead of the curve, public health authorities can implement targeted containment measures and mobilize resources more effectively, potentially averting catastrophic consequences. In the face of adversity, humanity’s greatest defense has always been the indomitable spirit of innovation and the relentless pursuit of knowledge. France’s push for emerging infectious disease research is a testament to this enduring truth – a testament that will undoubtedly echo through the ages as a shining example of society’s resilience in the face of daunting challenges. A Shared Responsibility, a Global Impact - Natalie May The unveiling of France’s Emerging Infectious Disease Research Plan underscores the nation’s recognition that strategic, long-term investments in scientific excellence are crucial to fortifying global health security. As the world grows increasingly interconnected through trade, travel, and human migration, the threat of rapidly spreading pandemics looms larger than ever before. However, bolstering society’s defenses against the next pandemic is not just a national imperative – it is a shared responsibility among nations. By positioning itself at the forefront of this battle, France is not only safeguarding its own populace but also contributing to a broader May 2024 www.eurohealthleaders.com 34

37. Stay in touch. Subscribe to Euro Health Leaders and get the magazine in print, & digital on www.eurohealthleaders.com Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com

39. Innovation distinguishes between a leader and a follower.

40. L E A D E R S EUR Health www.eurohealthleaders.com